What is CPR and why does it matter for fatty liver?

CPR (NADPH-cytochrome P450 oxidoreductase) is an enzyme that supports cytochrome P450 and redox proteins. It regulates lipid metabolism, bile acids, and oxidative stress - all relevant to MASLD - and the approved drug resmetirom boosts its expression.

Does this change what I should eat?

No. The food guidance is unchanged: the AASLD 2023 Mediterranean pattern, saturated fat control, added sugar minimized. The CPR work is mechanistic context, not a new dietary lever.

Is resmetirom available for MASLD?

Resmetirom is approved for MASH with moderate-to-advanced fibrosis in the US. It is a prescription decision with a clinician; this site's ratings are about food, not drug recommendations.

One Enzyme, Many Roads: CPR, Resmetirom, and the Future of MASLD Treatment

An August 2026 Nature Reviews Gastroenterology & Hepatology perspective makes the case that a single enzyme - NADPH-cytochrome P450 oxidoreductase, or CPR, encoded by the POR gene - sits at a surprising number of the pathways that go wrong in metabolic dysfunction-associated steatotic liver disease. CPR is the electron donor for microsomal cytochrome P450 enzymes and other redox proteins, which puts it at the intersection of lipid metabolism, xenobiotic processing, bile acid synthesis, and cellular redox balance.

The review pulls together genetic, biochemical, transcriptomic, and clinical evidence. Altered CPR activity is linked to hepatic lipid accumulation, oxidative stress, mitochondrial dysfunction, disturbed iron handling, ferroptosis, and inflammatory signaling. POR polymorphisms plus metabolic stress may help explain why two people with similar diets and weights progress so differently. And there is a translational hook: the approved MASH therapy resmetirom, a thyroid hormone receptor-beta agonist, increases POR transcription - suggesting that restoring CPR-associated pathways is already part of how a working drug does its job.

What an enzyme hub means for food

The CPR story is molecular, but its food-level translation is ordinary, because the pathways it touches - lipid handling, oxidative stress, inflammation - are the same ones the Mediterranean pattern and this site's ratings engage. Foods that support lipid oxidation and antioxidant defense (fish, legumes, vegetables, olive oil, nuts) nudge the biology in the protective direction; foods that load saturated fat and refined sugar push the opposite way.

The database makes this concrete. Walnuts rate Recommended in portion - about 6.1g saturated per 100g against a mostly unsaturated profile - and their polyphenol load supports redox balance. Olive oil, the Mediterranean's primary fat, is both the database's Recommended oil and a source of fat-soluble antioxidants. These are not medicines for POR; they are the pattern the biology favors.

How we covered a mechanistic review

Perspective pieces are interpretations, not new data, so our editorial process treats them differently. We read the CPR argument as a synthesis - a way to connect observations that were previously separate - and we checked that the translational claim about resmetirom was grounded in the published drug data before repeating it. We also kept the food guidance where it belongs: unchanged, because the AASLD 2023 framework does not depend on any single enzyme pathway.

What the perspective does add for readers is a reason the "same pattern, different outcomes" phenomenon is not mysterious: individual biology varies, and POR variation is part of that variation. The food response is still the pattern - saturated fat share low, added sugar rare, fiber high - because that pattern works across the biological spectrum.

The takeaway

CPR is emerging as a molecular bridge between metabolic disturbance and liver injury, and its role in resmetirom's mechanism gives the pathway clinical weight. For the person eating with a fatty liver in mind, the practical reading is short: the biology is complex, the food guidance is not. Recommended column, portion control, added-sugar veto, and regular clinical follow-up remain the operating system - whether the science is talking about one enzyme or a thousand.

The variability lesson: same diet, different trajectories

The most practical idea in the CPR perspective is that POR variation plus metabolic stress helps explain why two people with similar diets and weights can progress so differently. That is a useful antidote to the self-blame that sometimes accompanies fatty liver - and a reminder that individual biology is part of the picture. It does not change the dietary recommendation, because the Mediterranean pattern is protective across the biological spectrum, but it does explain why outcomes vary.

Our editorial framing for this: the food guidance is the part anyone can act on, and it is stage- and genotype-agnostic. The biology explains variation; the pattern manages the common levers.

How resmetirom connects to the food picture

The translational hook - resmetirom increasing POR transcription - is worth stating carefully. It means a working MASH drug touches this pathway, which strengthens the case that the pathway matters. It does not mean food can mimic the drug, and it does not mean anyone should expect a dietary equivalent. The food side is pattern-based: saturated fat share low, added sugar rare, fiber high, and the Recommended column as the default. The drug side is a prescription decision with a clinician. Both can be true at once, and the honest coverage keeps them separate.

Why precision medicine framing matters for readers

The CPR story is part of a larger shift toward molecular phenotyping in MASLD - the idea that the disease has subtypes with different drivers, and that treatments and monitoring might eventually be matched to the subtype. For a reader, the useful takeaway is that the heterogeneity of fatty liver is real and increasingly explainable. Some of it is POR variation, some is metabolic context, some is diet and activity. The food response does not depend on knowing which subtype applies, because the Mediterranean pattern and the saturated-share rule are protective across the spectrum.

We keep this framing in the coverage because it prevents both overconfidence (one size fits all) and fatalism (my biology is fixed). The pattern is the lever that works everywhere; precision tools are the future that will refine monitoring, not replace the pattern.

It is also worth noting what the CPR perspective does not do: it does not overturn the dietary guidance, and it does not promise a new food lever. The pathways it touches - lipid handling, redox balance, inflammation - are the same ones the Mediterranean pattern and this site's three criteria engage. The science adds depth to the map; the food guidance stays where it was, because the evidence for it does not depend on any single enzyme.

And for the reader who manages MASLD, the closing thought is the same one this site returns to: the biology is getting more detailed, and the food guidance is staying the same. That is not a failure of science - it is a sign the dietary pattern was right all along. The Recommended column, the saturated-share check, the added-sugar veto, and regular clinical follow-up are the durable operating system, and mechanistic papers like this one are context around it.

This is dietary reference information, not medical advice. Always consult your healthcare provider before making dietary changes.